Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

Cancer Discovery

Volumn 4, Issue 5, 2014, Pages 546-553

  Wagle, Nikhil ^a,b,d   Grabiner, Brian C ^d,e   Van Allen, Eliezer M ^a,b,d   Hodis, Eran ^d   Jacobus, Susanna ^a   Supko, Jeffrey G ^c   Stewart, Michelle ^d   Choueiri, Toni K ^a,b   Gandhi, Leena ^a,b   Cleary, James M ^a,b   Elfiky, Aymen A ^a,b   Taplin, Mary Ellen ^a,b   Stack, Edward C ^a,b   Signoretti, Sabina ^a,b   Loda, Massimo ^a,b,d   Shapiro, Geoffrey I ^a,b   Sabatini, David M ^d,e   Lander, Eric S ^d   Gabriel, Stacey B ^d   Kantoff, Philip W ^a,b   Garraway, Levi A ^a,b,d   Rosenberg, Jonathan E ^a,f   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PEPTIDES AND PROTEINS; S6 PROTEIN KINASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; CANCER GROWTH; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE ACTIVATION; GENE MUTATION; GENE SEQUENCE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOURICEMIA; IMMUNOBLOTTING; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE RIGIDITY; NAUSEA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; SOMATIC MUTATION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, TRANSITIONAL CELL; CASE REPORT; CHEMISTRY; CLINICAL TRIAL; DNA SEQUENCE; DRUG ADMINISTRATION; GENETICS; HIGH THROUGHPUT SEQUENCING; LYMPH NODE METASTASIS; MUTATION; PERSONALIZED MEDICINE; SCINTISCANNING; URINARY BLADDER NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; DRUG ADMINISTRATION SCHEDULE; EVEROLIMUS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PRECISION MEDICINE; PYRIMIDINES; SEQUENCE ANALYSIS, DNA; SULFONAMIDES; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84899680978     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0353     Document Type: Article

References (24)

1. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; 31: 1806-14.
2. Park SR, Davis M, Doroshow JH, Kummar S. Safety and feasibility of targeted agent combinations in solid tumours. Nat Rev Clin Oncol 2013; 10: 154-68.
3. Appleby L, Morrissey S, Bellmunt J, Rosenberg J. Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. Hematol Oncol Clin North Am 2011; 25: 893-915.
4. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8.
5. Escudier BJ, Porta C, Bono P, De Giorgi U, Parikh O, Hawkins RE, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol 30, 2012 (suppl; abstr CRA4502).
6. Motzer R, Hutson T, Reeves J, Hawkins R, Guo J, Nathan P, et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): results of the COMPARZ trial. Ann Oncol 2012; 23 (Suppl 9): LBA8.
7. O'Reilly T, Wood JM, Littlewood-Evans A, Boulay A, Schnell CR, Patrizia S, et al. Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: a rational basis for combining RAD001 and PTK787/ZK222584. Proc Am Assoc Cancer Res 2005; 46. Abstract nr 3038.
8. Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, Taguchi T, et al. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/ mammalian target of rapamycin signaling. Cancer Sci 2006; 97: 945-51.
9. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009; 15: 4220-7.
10. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39 (Database issue): D945-50.
11. Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A 2007; 104: 3514-9.
12. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
13. Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, Mizushima N, et al. Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 2008; 283: 31861-70.
14. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature 2013; 497: 217-23.
15. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011; 17: 4071-81.
16. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-51.
17. Klümpen H-J, Queiroz KCS, Spek CA, van Noesel CJM, Brink HC, de Leng WWJ, et al. mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome. J Clin Oncol 2011; 29: e150-3.
18. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CDM, Vena N, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010; 28: 835-40.
19. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.
20. Hardt M, Chantaravisoot N, Tamanoi F. Activating mutations of TOR (target of rapamycin). Genes Cells 2011; 16: 141-51.
21. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
22. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
24. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273: 239-42.